In a small sign of a possible improvement in the sluggish biotech initial public offering (IPO) market, Apogee Therapeutics has said it expects gross proceeds of $300 mill
Biotech watchers lamenting a fall-off in public listings for biotech companies will take some heart from Acelyrin’s upsized initial public offering, which ended up at the
Johnson & Johnson’s consumer health unit Kenvue looks set to raise $3.8 billion in an upsized initial public offering (IPO), valuing the business at around $41 billion
Initial public offerings in the biotech sector nosedived last year after a lot of activity in 2021, but have remained few and far between this year amid tough economic con
Exscientia's artificial intelligence-based drug discovery engine is still largely unproven, but that hasn't stopped the company raking in funding from investors keen to back its platform.
Shares in DNA sequencing specialist Oxford Nanopore rocketed after the company made its debut on the London Stock Exchange yesterday, rising nearly 50% to propel its valuation up towards th
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho